Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 8, 2012, Pages 780-789

  De Man, Frances S ^a,b,c   Tu, Ly ^a,b   Handoko, M Louis ^c   Rain, Silvia ^c   Ruiter, Gerrina ^c   François, Charlène ^a,b   Schalij, Ingrid ^c   Dorfmul̈ler, Peter ^a,b   Simonneau, Gérald ^a,b,d   Fadel, Elie ^a,b   Perros, Frederic ^a,b   Boonstra, Anco ^c   Postmus, Piet E ^c   Van Der Velden, Jolanda ^c   Vonk Noordegraaf, Anton ^c   Humbert, Marc ^a,b,d   Eddahibi, Saadia ^a,b   Guignabert, Christophe ^a,b  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Endothelial cells; Idiopathic pulmonary arterial hypertension; Monocrotaline; Renin angiotensin system; Smooth muscle cells

Indexed keywords

AMBRISENTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN ANTAGONIST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; LOOP DIURETIC AGENT; LOSARTAN; PROSTACYCLIN; RENIN; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; SPIRONOLACTONE; TREPROSTINIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HEART VENTRICLE OVERLOAD; HUMAN; LUNG ENDOTHELIUM; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; THERAPY EFFECT; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CASE-CONTROL STUDIES; CELLS, CULTURED; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LOSARTAN; MALE; MIDDLE AGED; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; PROPORTIONAL HAZARDS MODELS; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; UP-REGULATION;

EID: 84867589328     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201203-0411OC     Document Type: Article

References (38)

1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.
2. Handoko ML, de Man FS, Allaart CP, Paulus WJ, Westerhof N, Vonk-Noordegraaf A. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: Lessons from the left heart. Eur Respir Rev 2010;19:72-82.
3. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996;94:2285-2296. (Pubitemid 26360526)
4. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:1269-1275.
5. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012;5:97-105.
6. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-1585.
7. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;110:1308-1312. (Pubitemid 39202350)
8. Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion HC, Girgis RE, Hassoun PM. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:1364-1369. (Pubitemid 351860914)
9. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, et al. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: Increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 2003;4:27-30. (Pubitemid 36443383)
10. Chung WK, Deng L, Carroll JS, Mallory N, Diamond B, Rosenzweig EB, Barst RJ, Morse JH. Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. J Heart Lung Transplant 2009;28:373-379.
11. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 2000;192:379-384.
12. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010;50:439-465.
13. Leier CV, Bambach D, Nelson S, Hermiller JB, Huss P, Magorien RD, Unverferth DV. Captopril in primary pulmonary hypertension. Circulation 1983;67:155-161. (Pubitemid 13222085)
14. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:1048-1054.
15. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2011;182:1065-1072.
16. Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol 2008;75:781-786. (Pubitemid 351174108)
17. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912. (Pubitemid 32163892)
18. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-1407.
19. Okada M, Harada T, Kikuzuki R, Yamawaki H, Hara Y. Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J Pharmacol Sci 2009;111:193-200.
20. Rondelet B, Kerbaul F, Van Beneden R, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R. Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2005;289:H2319-H2324. (Pubitemid 41698538)
21. Rouleau JL, Kapuku G, Pelletier S, Gosselin H, Adam A, Gagnon C, Lambert C, Meloche S. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: Importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. Circulation 2001;104:939-944. (Pubitemid 32778047)
22. de Man FS, Guignabert C, Tu L, Francois C, Simonneau G, Fadel E, Humbert M, Vonk-Noordegraaf A, Eddahibi S. Increased renin-angiotensin-aldosterone system activity in lungs of patients with idiopathic pulmonary arterial hypertension [abstract]. Eur Respir J 2011;274S:P1516.
23. de Man FS, Guignabert C, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, Schalij I, Simonneau G, Fadel E, et al. The therapeutic potential of the renin-angiotensin-aldosteron system in idiopathic pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2012;185:A2494.
24. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, Dartevelle P, Simonneau G, Adnot S, Maitre B, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009;119:512-523.
25. Tu L, Dewachter L, Gore B, Fadel E, Dartevelle P, Simonneau G, Humbert M, Eddahibi S, Guignabert C. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:311-322.
26. Handoko ML, de Man FS, Happe CM, Schalij I, Musters RJ, Westerhof N, Postmus PE, Paulus WJ, van der Laarse WJ, Vonk-Noordegraaf A. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 2009;120:42-49.
27. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJ, Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:669-675.
28. de Man FS, van Hees HW, Handoko ML, Niessen HW, Schalij I, Humbert M, Dorfmuller P, Mercier O, Bogaard HJ, Postmus PE, et al. Diaphragm muscle fiber weakness in pulmonary hypertension. Am J Respir Crit Care Med 2011;183:1411-1418.
29. Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol 2007;27:2532-2539. (Pubitemid 350158902)
30. Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747-803. (Pubitemid 44033382)
31. Castrop H, Hocherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 2010;90:607-673.
32. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75:IV80-IV92.
33. Mehta PK, Griendling KK. Angiotensin ii cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-C97. (Pubitemid 46127306)
34. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997;29:366-373. (Pubitemid 27074070)
35. Li L, Zhou Y, Wang C, Zhao YL, Zhang ZG, Fan D, Cui XB, Wu LL. SRC tyrosine kinase regulates angiotensin II-induced protein kinase Czeta activation and proliferation in vascular smooth muscle cells. Peptides 2010;31:1159-1164.
36. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992;102:1407-1412.
37. Ikram H, Maslowski AH, Nicholls MG, Espiner EA, Hull FT. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. Br Heart J 1982;48:541-545. (Pubitemid 13217289)
38. van de Veerdonk M, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511-2519.